78 / 86
in Soft Tissue Sarcoma
Kawano S. el at. Mitotic and Non-Mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma. Anticancer Research April 2016 vol. 36 no. 4 1553-1561
Eribulin improves vascular perfusion in leiomyosarcoma xenograft
“Regardless of dose, all eribulin-treated groups showed significantly enhanced tumor blood
perfusion 5 days after administration compared to the vehicle control group”
Hoechst-positive areas were increased to 557%, 545%, and 349%